Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following...
Coronavirus
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing...
Spero Clinic Offers Hope for Long COVID Patients
Unique treatment program offers promising results for Long COVID patients who are experiencing extreme symptoms related to the virus.FAYETTEVILLE, AR...
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial...
Phase 1b/2 “RAINIER” Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidineCompany anticipates new data...
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with...
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...
NanoViricides Provides an Update on Its Clinical Program and Strategy – NV-387 Could be As Revolutionary as Antibiotics
SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens
High-throughput, high-content imaging-based assay developed to screen convalescent sera for neutralizing antibodies to SARS-CoV-2 variants Study highlights Tonix’s internal R&D...
Services PMI® at 51.4%; July 2024 Services ISM® Report On Business®
Business Activity Index at 54.5%; New Orders Index at 52.4%; Employment Index at 51.1%; Supplier Deliveries Index at 47.6% TEMPE,...
Manufacturing PMI® at 46.8%; July 2024 Manufacturing ISM® Report On Business®
New Orders and Backlogs Contracting; Production and Employment Contracting; Supplier Deliveries Slowing; Raw Materials Inventories Contracting; Customers' Inventories Too Low;...
“NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy”; “Novel Anti-Viral Could Boost a US$3 Billion Market” – Conclude Two Independent Research Reports on NanoViricides
SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone...
TE Connectivity announces third quarter results for fiscal year 2024
Delivered EPS above guidance driven by strong margin expansion; Record year-to-date cash flow SCHAFFHAUSEN, Switzerland, July 24, 2024 /PRNewswire/ --...
COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
SHELTON, CT / ACCESSWIRE / July 24, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a leader in men’s...
NewGenIvf Provides Update on Potential Reverse Merger with COVIRIX
BANGKOK, July 24, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider...
Pulse Oximetry Market size is set to grow by USD 1.18 billion from 2024-2028, Increasing prevalence of chronic respiratory diseases to boost the market growth, Technavio
NEW YORK, July 19, 2024 /PRNewswire/ -- The global pulse oximetry market size is estimated to grow by USD 1.18 billion from 2024-2028,...